Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Sugammadex Administration Under Deep Versus Light Sevoflurane Anesthesia on Recovery Characteristics and Complications in Children Undergoing Adenoidectomy or Adenotonsillectomy: A Prospective Observational Cohort Study

NCT07902193 is registered in ClinicalTrials.gov with Namik Kemal University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07902193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Sugammadex Administration Under Deep Versus Light Sevoflurane Anesthesia on Recovery Characteristics and Complications in Children Undergoing Adenoidectomy or Adenotonsillectomy: A Prospective Observational Cohort Study
Lead sponsor
Namik Kemal University
Phase
Observational
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
November 30, 2029
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

delayed emergence from anesthesia, emergence agitation, neuromuscular blockade

Arms

As registered; 2 arms.

  • Deep reversal

    Children who receive sugammadex 4 mg/kg while end-tidal sevoflurane is 1.0-1.1 MAC, as decided by the attending anesthesiologist in routine practice.

    Intervention: Drug: Sugammadex. Administered as part of routine care; not assigned by the investigators.

  • Light reversal

    Children who receive sugammadex 4 mg/kg after end-tidal sevoflurane has decreased to 0.3-0.4 MAC, as decided by the attending anesthesiologist in routine practice.

    Intervention: Drug: Sugammadex. Administered as part of routine care; not assigned by the investigators.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Time to extubation From sugammadex administration to tracheal extubation, assessed up to 60 minutes

    Time from sugammadex administration to tracheal extubation, in minutes and seconds. Time from end of surgery to extubation will also be recorded.

Lead sponsor's other trials

Namik Kemal University, most recent start first.

Similar trials

Same condition (Delayed Emergence from Anesthesia) and phase, most recent start first.